Kymera Therapeutics, Inc.
KYMR
株式のランク
#2299
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
株価
$105.36
最終同期: 2026-10-16
時価総額
$8.67B
変化（1日）
-2.57%
変化（1年）
76.10%
国
US
取引 Kymera Therapeutics, Inc. (KYMR)
カテゴリー
Healthcare
Kymera Therapeutics, Inc.（KYMR）の営業利益率
October 2026 時点の営業利益率 TTM: -333.54%
Kymera Therapeutics, Inc. の最新の財務報告と株価によると、現在の営業利益率（TTM）は -333.54% です。2023 年末時点では -210.62% でした。
Kymera Therapeutics, Inc. の営業利益率の履歴（2018 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | -333.54% | -39.99% |
| 2024 | -555.82% | 163.90% |
| 2023 | -210.62% | -38.84% |
| 2022 | -344.37% | 149.49% |
| 2021 | -138.03% | 1.46% |
| 2020 | -136.05% | -90.54% |
| 2019 | -1,438.48% | 0.00% |
| 2018 | 0.00% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -100.12% |
US
|
|
| -149.01% | -99.55% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.09% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。